Zymeworks (ZYME) Secures FDA Approval And $250 Million Milestone, Is The Stock Still Undervalued?

Simply Wall St.

Aug 27

The latest move in Zymeworks (ZYME) stock comes after the U.S. FDA approved Ziihera, or zanidatamab hrii, for first line treatment of certain HER2 positive gastroesophageal cancers, triggering a US$...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2662745771"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2662745771\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2662745771?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-08-27 13:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2662745771","market":"nz","top_or_hot":-1,"title":"Zymeworks (ZYME) Secures FDA Approval And $250 Million Milestone, Is The Stock Still Undervalued?","media":"Simply Wall St.","content":"<div>\n<p>The latest move in Zymeworks (ZYME) stock comes after the U.S. FDA approved Ziihera, or zanidatamab hrii, for first line treatment of certain HER2 positive gastroesophageal cancers, triggering a US$...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/zymeworks-zyme-secures-fda-approval-and-250-million-mileston\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zymeworks (ZYME) Secures FDA Approval And $250 Million Milestone, Is The Stock Still Undervalued?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZymeworks (ZYME) Secures FDA Approval And $250 Million Milestone, Is The Stock Still Undervalued?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-27 13:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/zymeworks-zyme-secures-fda-approval-and-250-million-mileston><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The latest move in Zymeworks (ZYME) stock comes after the U.S. FDA approved Ziihera, or zanidatamab hrii, for first line treatment of certain HER2 positive gastroesophageal cancers, triggering a US$...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/zymeworks-zyme-secures-fda-approval-and-250-million-mileston\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZYME","symbol_name":"ZYMEWORKS INC (US)","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/zymeworks-zyme-secures-fda-approval-and-250-million-mileston","article_id":"2662745771","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zyme/zymeworks/news/zymeworks-zyme-secures-fda-approval-and-250-million-mileston","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2662745771","pubTimestamp":1787807892,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"The latest move in Zymeworks (ZYME) stock comes after the U.S. FDA approved Ziihera, or zanidatamab hrii, for first line treatment of certain HER2 positive gastroesophageal cancers, triggering a US$250 million milestone from partner Jazz Pharmaceuticals.\nThe FDA decision appears to have reinforced investor confidence in Zymeworks, with the stock posting a 27.41% 1 month share price return and a 96.28% 1 year total shareholder return, while the 298.71% 3 year total shareholder return points to...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZYME":"ZYMEWORKS INC (US)","BK4588":"碎股","BK4585":"ETF&股票定投概念","LABU":"三倍做多标普生物-Direxion","BK4139":"生物科技"},"translate_title":"Zymeworks (ZYME) 获得 FDA 批准并达到 2.5 亿美元里程碑，该股仍被低估吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"ZYME":1.5},"content_text":"The latest move in Zymeworks (ZYME) stock comes after the U.S. FDA approved Ziihera, or zanidatamab hrii, for first line treatment of certain HER2 positive gastroesophageal cancers, triggering a US$250 million milestone from partner Jazz Pharmaceuticals. The FDA decision appears to have reinforced investor confidence in Zymeworks, with the stock posting a 27.41% 1 month share price return and a 96.28% 1 year total shareholder return, while the 298.71% 3 year total shareholder return points to momentum that has been sustained over a longer period. Track how Zymeworks fits into a wider biotech toolkit by scanning a curated 20 high quality undiscovered gems, which are also leveraging partnerships and pipelines to pursue growth in complex diseases. Zymeworks now has an FDA approved drug, a large milestone payment and a long track record of volatile returns. The next step is simple: do these strengths still justify the current share price after the latest jump? AdvertisementMost Popular Narrative: 25.3% Undervalued The most followed narrative on Zymeworks compares a fair value of $39.23 to the last close at $29.31, which frames the recent rally as only part of the story.  The increasing global incidence of cancer and chronic diseases, driven by an aging population, is expanding the potential market for Zymeworks' oncology and biologic therapies, positioning its diversified pipeline (including ADCs like ZW171, ZW191, ZW251, and zanidatamab) for long-term addressable revenue growth as regulatory approvals, new indications, and commercial launches progress.  Read the complete narrative. Want to see what sits behind that growth blueprint for Zymeworks? The central storyline links rapid top line expansion, shifting margins, and a rich future earnings multiple into one valuation view. Result: Fair Value of $39.23 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the Zymeworks narrative still hinges on irregular milestone payments and early stage pipeline assets, where clinical or regulatory setbacks could quickly challenge today’s valuation story. Find out about the key risks to this Zymeworks narrative. Next Steps If this Zymeworks story sounds promising, use the momentum as a cue to review the numbers yourself and stress test the upside case. To see why some investors are focused on the potential rewards, take a closer look at the 2 key rewards Looking for more Zymeworks style investment ideas? If Zymeworks has sharpened your interest, do not stop here. Use the Simply Wall St screener to explore opportunities that align with your own risk and return preferences.  Explore potential upside in established businesses by scanning the 51 high quality undervalued stocks that combine solid fundamentals with pricing that may not fully reflect their profiles. Prioritise resilience by focusing on companies with strong finances using the list of solid balance sheet and fundamentals (51 results) to keep capital preservation prominent in your process. Build a steadier income stream by reviewing the 11 dividend fortresses that pair higher yields with businesses aiming to support ongoing shareholder payouts.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Zymeworks might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}